Franklin Genomic Advancements I EUR

Investment Objective To seek long-term investment growth, through growth of capital. Investment Policy The Fund mainly invests in equities of companies of any market capitalisation that are related to genomic-based technologies designed to enhance the quality of life, including DNA sequencing, gene editing, and personalised medicine. These investments may be from anywhere in the world, including emerging markets.These investments may include convertible securities. To a lesser extent, the Fund may invest in corporate bonds of any quality worldwide.SFDR category Article 8 (promotes environmental and/or social characteristics under EU regulations).The investment manager applies a proprietary rating methodology using various ESG criteria to assess long-term opportunities and risks. The fund also excludes or restricts investments in certain industries that are harmful to the environment or society, such as thermal coal, weapons and tobacco. The investment manager engages in dialogue with companies concerning ESG issues.For more information see www.franklintempleton.lu/32168Base currency US dollar (USD).Benchmark(s) MSCI All Country World Index-NR. Used for performance comparison only.The Fund is actively managed and may deviate materially from that of the benchmark(s). Share Class Policy Buying and selling shares You may normally buy or sell shares on any day the New York Stock Exchange is open for business. The income received from the Fund's investments is accumulated with the result of increasing the value of the shares.

PIR compliant

No

PEA compliant

No

PEA-PME compliant

No